Law360 (March 20, 2020, 4:47 PM EDT) -- The Patent Trial and Appeal Board has invalidated the overwhelming majority of claims Hybrigenics SA challenged in a Forma Therapeutics Inc. patent for a potential cancer treatment for lack of written description support, while at the same time upholding a single claim.

The board's decision, which was issued Thursday, came in a post-grant review of the patent, which relates to inhibitors of the enzyme ubiquitin-specific protease 7, which the patent says "has the potential to be a treatment for cancers and other disorders."

Click here to read this article in its entirety.